Pancragen
Khavinson tetrapeptide bioregulator targeting pancreatic tissue — studied for beta-cell function restoration, insulin synthesis support, and metabolic regulation.
🔬 Mechanism of Action
Pancragen (Lys-Glu-Asp-Trp, KEDW) is a synthetic tetrapeptide bioregulator targeting pancreatic beta cells. The KEDW sequence was selected through systematic screening of pancreas-derived peptide fractions for insulin gene promoter activity.
Pancragen modulates gene expression for (1) insulin synthesis via PDX-1 and MafA transcription factors, (2) glucose sensor proteins including GLUT2 transporter and glucokinase, and (3) beta-cell survival pathways that protect against glucotoxicity and lipotoxicity. In streptozotocin-induced diabetes models, Pancragen treatment improved glucose-stimulated insulin secretion by 40-50%.
Pancragen represents the synthetic targeted approach to pancreatic support, while its Cytomax counterpart Suprefort provides broader exocrine and endocrine support.
Source: PMID: 15677927
📜Background & History
Pancragen (KEDW) targets pancreatic beta cells for insulin synthesis support.
🎯 Research Use Cases
- ✓Metabolic support
- ✓Beta-cell preservation
- ✓Pre-diabetic protocols
💉 Dosing Protocol
| Typical Dose | 10-20 mg/day (oral) or 1-2 mg SC |
| Frequency | 1× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Standard Khavinson protocol. Monitor blood glucose in diabetic patients. Can be combined with Suprefort (pancreatic Cytomax extract) for comprehensive pancreatic support.
⚡Interactions & Contraindications
Monitor blood glucose in diabetic patients.
🔗Synergies & Common Stacks
Pancragen (synthetic beta-cell targeted) + Suprefort (whole pancreas Cytomax) = comprehensive pancreatic support.